Product
TY-2136b
1 clinical trial
2 indications
Indication
Locally Advanced Solid TumorIndication
Metastatic Solid TumorClinical trial
A Phase I, Multicenter, Open-label Study of TY-2136b, Administered Orally in Patients With Advanced or Metastatic Solid Tumors Harboring ALK, ROS1 or NTRK1-3 AlterationsStatus: Recruiting, Estimated PCD: 2025-01-01